Keyword: Giovanni Caforio
Bristol CEO Caforio figures the company's Celgene buy will fortify its position regardless of where the ongoing drug pricing debate goes.
Bristol-Myers is counting on new talent from Novartis and Celgene—and a revamped R&D chart—to buck up its existing drugs and new launches.
Bristol-Myers Squibb plans to take on tens of billions in new debt to fund its Celgene buy, but execs have said they plan to quickly pay it down.
Bristol-Myers CEO Giovanni Caforio's 2018 pay package gained on revenue growth and Celgene negotiations—but took a hit from R&D results.
Analysts pounded the CEOs of BMS and Celgene for details about their integration plans. But investors seemed dissatisfied with their answers.
Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.
On Dec. 10, Bristol-Myers Squibb made what it said was its final offer to buy Celgene. But it ended up striking a better deal instead.
Ever wish you could be a fly on the wall at a company in the middle of a merger? Thanks to the Securities and Exchange Commission, you can.
BMS execs faced a tough audience during its Q4 report, as analysts pressed them for details about how the Celgene merger would drive growth.